Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Global Market Report 2025

The vesicular monoamine transporter 2 (VMAT2) inhibitor market size has grown rapidly in recent years. It will grow from $1.13 billion in 2024 to $1.25 billion in 2025 at a compound annual growth rate (CAGR) of 10.6%. The growth during the historic period can be attributed to the rising prevalence of movement disorders, an increasing demand for effective treatment options, greater awareness of tardive dyskinesia, a growing geriatric population, and a higher preference for oral formulations.

The vesicular monoamine transporter 2 (VMAT2) inhibitor market size is expected to see rapid growth in the next few years. It will grow to $1.85 billion in 2029 at a compound annual growth rate (CAGR) of 10.3%. The projected growth in the forecast period can be attributed to the rising incidence of neurodegenerative diseases, a growing adoption of targeted therapies, an increasing focus on personalized medicine, more investment in research and development, and heightened awareness of psychiatric and movement disorders. Key trends during this period include advancements in neurological research, improvements in drug formulations, a shift toward personalized and precision medicine, the development of next-generation VMAT2 inhibitors, and the integration of digital health technologies.

The growing prevalence of Parkinson's disease is expected to drive the expansion of the vesicular monoamine transporter 2 (VMAT2) inhibitor market. Parkinson's disease is a progressive neurological disorder that impairs movement due to the loss of dopamine-producing cells in the brain. The increasing prevalence of Parkinson's is primarily attributed to an aging population, improved diagnosis, environmental factors such as exposure to toxins, genetic factors, and increased awareness of the condition. VMAT2 inhibitors help manage Parkinson's symptoms by regulating dopamine release, reducing tremors, and controlling dyskinesia. For example, in December 2022, the Parkinson's Foundation reported that nearly 90,000 people were diagnosed with Parkinson's disease in the U.S., a 50% increase compared to the previous estimate of 60,000 annual diagnoses. As a result, the rising prevalence of Parkinson's disease is propelling the growth of the VMAT2 inhibitor market.

Leading companies in the VMAT2 inhibitor market are focusing on developing innovative formulations such as capsules to improve patient compliance, enhance drug stability, and optimize therapeutic outcomes. Capsules, which are solid dosage forms enclosed in gelatin or HPMC shells, benefit VMAT2 inhibitors by ensuring precise dosing, improving drug stability, and supporting patient adherence. For example, in July 2024, Neurocrine Biosciences Inc. launched Ingrezza Sprinkle (valbenazine) capsules, a new formulation of the VMAT2 inhibitor Ingrezza. This version is designed to facilitate administration for adults with tardive dyskinesia and chorea associated with Huntington's disease who have difficulty swallowing. Ingrezza Sprinkle provides the same effective dosing options as Ingrezza but can be taken by sprinkling the contents onto soft food or swallowing the capsule whole.

In March 2024, Bristol Myers Squibb, a U.S.-based pharmaceutical company, acquired Karuna Therapeutics for $14 billion. This acquisition enables Bristol Myers Squibb to enhance its neurology portfolio by gaining access to Karuna Therapeutics' promising pipeline, including the VMAT2 inhibitor KarXT. KarXT has the potential to address unmet needs in psychiatric disorders such as schizophrenia, expanding Bristol Myers Squibb's therapeutic offerings and accelerating its growth in the neuroscience sector. Karuna Therapeutics is a U.S.-based biopharmaceutical company that specializes in VMAT2 inhibitor treatments.

Major players in the vesicular monoamine transporter 2 (vmat2) inhibitor market are Thermo Fisher Scientific Inc., Eli Lilly and Company, Merck KGaA, Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Otsuka Pharmaceutical, Astellas Pharma, Bausch Health Companies Inc., Avantor Inc., Sun Pharmaceutical Industries Limited, Sumitomo Dainippon Pharma, Dr. Reddy’s Laboratories Ltd., H. Lundbeck A/S, Hikma Pharmaceuticals plc, Lupin Limited, Neurocrine Biosciences Inc., Luye Pharma Group Ltd., Ventegra Inc., Mitsubishi Tanabe Pharma Corporation, Biomol GmbH.

North America was the largest region in the vesicular monoamine transporter 2 (VMAT2) inhibitor market in 2024. The regions covered in vesicular monoamine transporter 2 (VMAT2) inhibitor report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the vesicular monoamine transporter 2 (VMAT2) inhibitor market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

A vesicular monoamine transporter 2 (VMAT2) inhibitor is a drug that blocks VMAT2, a protein responsible for transporting monoamines such as dopamine, serotonin, and norepinephrine into synaptic vesicles for release in the brain. These inhibitors are used to manage neurological and psychiatric disorders by reducing excessive neurotransmitter release, particularly dopamine, and are effective in treating conditions such as tardive dyskinesia, Huntington’s disease, and other hyperkinetic movement disorders.

The main drugs in the VMAT2 inhibitor category include tetrabenazine, deutetrabenazine, valbenazine, and others. Tetrabenazine is a well-known VMAT2 inhibitor that treats movement disorders by lowering dopamine levels in the brain. These medications are administered via various routes, including oral and other methods, and are distributed through hospital pharmacies, online pharmacies, and retail pharmacies. They are used for various conditions such as Huntington’s disease, tardive dyskinesia, and other movement disorders. The primary end users of these drugs include hospitals, homecare settings, specialty clinics, and other healthcare facilities.

The vesicular monoamine transporter 2 (VMAT2) inhibitor market research report is one of a series of new reports that provides vesicular monoamine transporter 2 (VMAT2) inhibitor market statistics, including the vesicular monoamine transporter 2 (VMAT2) inhibitor industry global market size, regional shares, competitors with the vesicular monoamine transporter 2 (VMAT2) inhibitor market share, detailed vesicular monoamine transporter 2 (VMAT2) inhibitor market segments, market trends, and opportunities, and any further data you may need to thrive in the vesicular monoamine transporter 2 (VMAT2) inhibitor industry. This vesicular monoamine transporter 2 (VMAT2) inhibitor market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The vesicular monoamine transporter 2 (VMAT2) inhibitor market consists of sales of products such as deutetrabenazine, valbenazine, and tetrabenazine. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.